Watch and Wait for NeoAdjuvant Concurrent Radiochemotherapy Combined With Camrelizumab in Patients With Resectable ESCC
Clinical trial NCT05507411 · RECRUITING
Trial details
- NCT number
- NCT05507411
- Sponsor
- Zhejiang Cancer Hospital
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-08-03
- Primary completion
- 2024-04-01
- Enrollment
- 100
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.